Credit Suisse Ag Stoke Therapeutics, Inc. Transaction History

Credit Suisse Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$3.78 - $11.99 $4,014 - $12,733	-1,062 Reduced 7.86%	12,449 $49,000
Q2 2023 Aug 11, 2023	BUY	$7.93 - $13.82 $107,142 - $186,722	13,511 New	13,511 $143,000
Q4 2022 Feb 13, 2023	BUY	$7.07 - $15.69 $141 - $313	20 Added 0.2%	9,859 $90,000
Q3 2022 Nov 10, 2022	BUY	$12.56 - $22.53 $1,369 - $2,455	109 Added 1.12%	9,839 $126,000
Q2 2022 Aug 12, 2022	BUY	$10.36 - $23.93 $100,802 - $232,838	9,730 New	9,730 $129,000
Q2 2021 Aug 16, 2021	SELL	$30.53 - $41.09 $187,790 - $252,744	-6,151 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$36.08 - $69.81 $253,065 - $489,647	-7,014 Reduced 53.28%	6,151 $238,000
Q4 2020 Feb 12, 2021	BUY	$33.62 - $61.93 $197,820 - $364,396	5,884 Added 80.81%	13,165 $815,000
Q3 2020 Nov 13, 2020	BUY	$22.23 - $37.48 $161,856 - $272,891	7,281 New	7,281 $243,000

125

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $367M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.